Vir has deep immunology expertise that we are harnessing to address infectious diseases, viral-associated diseases and immune targeting.
Our growth and pursuit of scientific innovation is fueled by our leading monoclonal antibody (mAb) platform that has a proven track record and is further strengthened by our artificial intelligence-led mAb optimization and engineering capabilities.
Vir has built a broad pipeline with several ongoing trials – including two late-stage programs in chronic hepatitis delta and chronic hepatitis B – that we believe will support near- and long-term growth, along with multiple potential INDs in the next 12-24 months.
“Vir has proven that it can power the human immune system to fight viruses and engineer human-derived antibodies into powerful medicines. Our ability to develop impactful medicines for major public health challenges is a testament to the company’s deep knowledge of immunology and our ability to understand the interplay between viruses and the human immune system.”
– CEO Marianne De Backer, M.Sc., Ph.D., MBA
An Experienced Leadership Team
We have an industry-leading management team and Board of Directors with significant immunology and infectious diseases experience, including a proven track record of progressing product candidates from early-stage research through clinical development, and worldwide regulatory approval and commercialization.
Join Us in Our Mission to Deliver Transformative Medicines
We offer the opportunity to do challenging, rewarding work as part of our world class teams in the U.S. and Europe. If you share our goal of addressing the unmet needs of patients around the world, please visit our careers page for open positions.